Martín Lázaro

José Antonio Marina, filósofo: «La felicidad es satisfacer tres necesidades: el bienestar personal ... theobjective.com/lifestyle/2026…

Real-world study of apalutamide and enzalutamide in metastatic hormone-sensitive #ProstateCancer. @bilenma @EmoryUniversity joins @neerajaiims @huntsmancancer to discuss this analysis which followed FDA guidance for real-world evidence, requiring pre-planned protocols with defined study design, endpoints, and statistical methodology before data analysis. #WatchNow on UroToday > bit.ly/43iLvOp

UC Takeaways from #ASCOGU26 1) KEYNOTE-B15 is a landmark. Periop EV+pembro vs gem/cis in cis-eligible MIBC: EFS HR 0.53, pCR 55.8% vs 32.5%, OS benefit. First regimen to displace cisplatin in curative-intent bladder cancer in ~25 yrs.

What REALLY makes a good oncologist? in @JCO_ASCO After 10 years and 203 JCO essays, one thing became clear: expertise alone isn’t enough. Patient-centered care. Clear, authentic communication. Emotional intelligence. And the harder work Showing up again and again. Openness to uncertainty. Carrying the burden of cancer care. Continuous growth. Clinical competence is expected Human connection makes the difference. Science treats disease. Presence treats fear. ascopubs.org/doi/pdf/10.120… @OncoAlert

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors in @ESMO_Open. Evidence-based consensus statements providing guidance on the safety of combining RT with EGFR, ALK, or BRAF/MEK inhibitors. esmoopen.com/article/S2059-…

Agree with @Uromigos @tompowles1 about @rohitjainMD huge effort to get this pilot trial done, showing feasibility, manageable toxicity & impressive efficacy signal with EV/erda in pretreated mUC. Interested to see FORAGER-2 in 1L setting #GU26 @OncoAlert @FaltasLab @DrScottTagawa x.com/uromigos/statu…

IMVIGOR011: ctDNA guided adjuvant atezolizumab in MIBC shows a ctDNA risk adapted approach identified high risk patients who benefit from ICI therapy, sparing persistently ctDNA-ves (at much lower risk) toxicity. Here #GU26 we show ctDNA+ves have dynamic MTM levels (a bit like PSA). ⬆️ MTM levels have poor prognosis. MTM reduction with atezo = better outcomes. But low MTM at baseline levels still do poorly (compared to persistently negatives) meaning all ctDNA +ves are at risk. These data suggests MTM levels adds useful prognostic information beyond the binary ctDNA +ve vs ctDNA -ve status. @OncoAlert

Disitimab Vedotin (HER2/MMAE ADC) was tested in HER2-positive (n=73, RR 55%) and HER2-low (n=78, RR 53%) pretreated advanced bladder cancer outside of China. No clear efficacy difference according to HER status(PFS 6 months and OS 17-20 mnths). Only about 20% of UC patients are HER2 negative. Cumulative neuropathy is like EV, but perhaps less skin rash. It doesn’t have any clear advantages over EV. Sequencing data with EV suggests a lack of complete cross resistant - more date needed). The randomised phase 3 DVP vs. Chemo 1st line trial is complete. #GU26

ASCO GU 2026 – Top 15 Trials with Potential Practice Impact @ASCO #GU26

RT @tactics_md: Damos la bienvenida al #OncoPrecision26 con la apertura institucional y científica del simposio. Vigo se convierte en pun…

OncoAlert🚨The #AUC3 WEEK 2026 Their Publication is NOW OUTARTICLE HERE: 👉 buff.ly/bAgkPQC Presenter Dr. Brian Rini 🇺🇸 (Adjuvant Therapy Debate) CON in #KidneyCancer RCC Conclusions There are relevant data points on both sides of the benefit:risk equation to consider in the application of adjuvant pembro in individual resected high-risk RCC patients Benefits are real but modest with some missing information about the appropriate treatment of recurrence Life-altering toxicity in patients who may not recur is sobering RAMPART supports the benefit of adjuvant IO, and highlights confinement of the benefit to the highest risk patients We need better prognostication tools and predictive/prognostic biomarkers (?KIM-1) This is about to get more complicated with Pembro/belzu.. @DrRanaMcKay @montypal @DrRosenbergMSK @Wanling50578056 @Dr_Aggen @AlbigesL @apolo_andrea @OncoBellmunt @bergsa83 @bilenma @BraunMDPhD @drjefstathiou @PGrivasMDPhD @shilpaonc @arihakimi @HHammersMD @DrDanielHeng @MichelleDunno17 @EJonasch @koshkin85 @advocatekidneys @UrogerliMD @SurenaMatinMD @maughanonc @BradMcG04 @JoshMeeks @motzermd @AndreaNecchi @SimaPorten @tompowles1 @brian_rini @sonpavde @ChadTangMD @MichvdHeijden @VincentWenxinXu @TiansterZhang @Mustafajsalehmd @mzugman @AUC3_Official #kidneyCancer #BladderCancer

FORMULA-509 @EUplatinum 2026 pubmed.ncbi.nlm.nih.gov/41672869/ Can we safely intensify short-course ADT during salvage RT after prostatectomy? @DrPaulNguyen @DrRanaMcKay 345 pts, sRT + 6 mo GnRH agonist ▪️ Bicalutamide ▪️ vs Abiraterone + Prednisone + Apalutamide 🎯 Overall population ▪️ 3-yr PFS: 74.9% vs 68.5% HR 0.71 (p=0.063) ▪️ 3-yr MFS: 90.6% vs 87.2% HR 0.57 (p=0.050) ➡️ Did not meet prespecified statistical significance. 🔎 But here is the signal: In pts with PSA >0.5 ng/mL: ▪️ 3-yr PFS: 67.2% vs 46.8% HR 0.50 (p=0.030) ▪️ 3-yr MFS: 84.3% vs 66.1% HR 0.32 (p=0.014) 📌 Absolute MFS benefit: 18.2% 📌 NNT ≈ 5.5 💡 Interpretation: • Not practice-changing for all • Potentially relevant for biologically higher-risk salvage • Raises the key question: 👉 Is 6 months of intensified AR-axis suppression preferable to longer conventional ADT strategies? Quality of life vs oncologic control, the real tension. @OncoAlert @APCCC_Lugano @Silke_Gillessen @AOmlin @Prof_Nick_James @BertrandTOMBAL @LoebStacy @urotoday @ecancer @MedicalwatchHQ #ProstateCancer #SalvageRadiotherapy #ADT #ARPI #EurUrol #GUoncology

Última oportunidad para sumarte a #OncoPrecision26 📍 Vigo · 19–20 feb 2026 La #OncologíadePrecisión ya forma parte de la práctica clínica: NGS, IA, nuevas dianas terapéuticas y aplicación real en consulta, de la mano de especialistas de referencia a nivel nacional. ‼️👇 Mañana se cierran INSCRIPCIONES: tacticsmd.net/actividad/viii… @OncoHULA @mlazqui @SOG_Galicia

Millones de visitantes, vecinos hartos y Vigo contra Badalona: ¿cómo llegaron a esto las luces de Navidad? elpais.com/icon/2025-12-1…

Leído en ⁦@applesfera⁩ : “He viajado a Viena sin hablar alemán confiando solo en la traducción de los AirPods: sorprende, pero no es perfecta” applesfera.com/airpods/he-via…

Tissue and peripheral T cell receptor repertoire predicts immunotherapy response and progression-free survival in NSCLC patients nature.com/articles/s4159…

Los algoritmos adivinan cómo somos o cuánto ganamos solo con analizar nuestra foto theconversation.com/los-algoritmos…

Me hace mucha ilusión compartir que somos finalistas en #INNOVAH2025 🙌 Con Código Rojo queremos transformar la forma en la que los médicos acceden a conocimiento y formación, usando #IA como aliada ¿Nos echas una mano con un ❤️ y un RT? @NovartisSpain @SETH__Oficial @sehh_es

Seis cosas que los médicos de urgencias desearían que evitaras nytimes.com/es/2025/09/06/…

Real-world data on avelumab in first-line maintenance therapy for advanced or metastatic urothelial carcinoma: the SOGUG-AVELUMAB RWD study | Clinical and Translational Oncology link.springer.com/article/10.100…